Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03563846 · ClinicalTrials.gov registry record · Phase 1
Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Adult Male and Female Subjects
A Phase 1 study, sponsored by Ritter Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT03563846 is a Phase 1 study that has completed, run by Ritter Pharmaceuticals. The registered enrollment target is 14 participants.
The verdict
NCT03563846, a Phase 1 study, has completed, sponsored by Ritter Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
Randomized, open-label, 2-period, 2-sequence, crossover study to evaluate the effect of a standard meal on the pharmacokinetic (PK) profile of orally administered RP-G28.
Interventions
- DRUG RP-G28
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-03-09 |
| Est. Completion | 2018-04-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03563846
The ClinicalTrials.gov registry entry for NCT03563846 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ritter Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RP-G28 is the first listed.
NCT03563846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03563846 about?
NCT03563846 is a clinical study titled "Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Adult Male and Female Subjects". Randomized, open-label, 2-period, 2-sequence, crossover study to evaluate the effect of a standard meal on the pharmacokinetic (PK) profile of orally administered RP-G28.
What is the current status of trial NCT03563846?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2018-03-09. Estimated completion is 2018-04-13.
What interventions are being tested in trial NCT03563846?
The interventions under investigation include: RP-G28 (DRUG).
Who is sponsoring clinical trial NCT03563846?
This trial is sponsored by Ritter Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.